MeSH term
Frequency | Condition_Probility | Adult | 70 | 0.0 |
Comparative Study | 39 | 0.0 |
Humans | 370 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Follow-Up Studies | 6 | 0.0 |
Male | 150 | 0.0 |
Middle Aged | 41 | 0.0 |
Treatment Outcome | 8 | 0.0 |
Case-Control Studies | 3 | 0.0 |
*Chromosomes, Human, Y | 5 | 41.0 |
*Gene Deletion | 13 | 1.0 |
Polymerase Chain Reaction/methods | 8 | 0.0 |
Prospective Studies | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 204 | 0.0 |
Sequence Tagged Sites | 55 | 19.0 |
Arylsulfatases/*metabolism | 2 | 66.0 |
Base Sequence | 87 | 0.0 |
Female | 146 | 0.0 |
Gene Expression Regulation, Enzymologic/*drug effects | 2 | 1.0 |
Interleukin-1/*pharmacology | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Steryl-Sulfatase | 100 | 89.0 |
Chromosome Mapping | 65 | 0.0 |
Genome, Human | 10 | 2.0 |
Molecular Sequence Data | 92 | 0.0 |
Sequence Analysis, DNA | 14 | 0.0 |
Chromosomes, Human, Pair 5/*genetics | 2 | 2.0 |
*Gene Duplication | 2 | 1.0 |
Infant, Newborn | 11 | 0.0 |
Pregnancy | 17 | 0.0 |
Prenatal Diagnosis | 2 | 1.0 |
Electrophoresis, Gel, Pulsed-Field | 4 | 1.0 |
Phylogeny | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 112 | 0.0 |
Arylsulfatases/deficiency/*genetics | 5 | 100.0 |
Ichthyosis, X-Linked/enzymology/*genetics | 5 | 100.0 |
Mexico | 2 | 2.0 |
*Chromosome Mapping | 22 | 1.0 |
Chromosomes, Artificial, Bacterial/genetics | 2 | 4.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 25 | 0.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 2 | 1.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Staurosporine/pharmacology | 2 | 1.0 |
Chromosome Breakage | 3 | 3.0 |
Chromosome Deletion | 11 | 1.0 |
Chromosome Mapping/methods | 4 | 3.0 |
Gene Deletion | 6 | 0.0 |
Homozygote | 2 | 0.0 |
Tumor Cells, Cultured | 22 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Adolescent | 26 | 0.0 |
*Chromosome Deletion | 30 | 3.0 |
*Y Chromosome | 17 | 13.0 |
Neoplasm Staging | 6 | 0.0 |
Contig Mapping | 7 | 4.0 |
Oligospermia/*genetics | 6 | 12.0 |
Seminal Plasma Proteins/*genetics | 2 | 40.0 |
*Sequence Deletion | 3 | 0.0 |
Syndrome | 10 | 0.0 |
Y Chromosome | 6 | 7.0 |
Aged | 26 | 0.0 |
Arylsulfatases/*biosynthesis | 2 | 100.0 |
Immunohistochemistry | 8 | 0.0 |
Survival Rate | 5 | 0.0 |
Substrate Specificity | 6 | 0.0 |
Family Health | 6 | 0.0 |
*Heterozygote Detection | 3 | 2.0 |
In Situ Hybridization, Fluorescence | 36 | 1.0 |
Child | 31 | 0.0 |
Magnetic Resonance Imaging | 5 | 0.0 |
Temporal Lobe/*physiology | 2 | 33.0 |
Arylsulfatases/genetics | 9 | 75.0 |
Chromosome Banding | 12 | 1.0 |
Homeodomain Proteins/genetics | 2 | 0.0 |
Karyotyping | 20 | 1.0 |
Translocation, Genetic | 8 | 1.0 |
X Chromosome/*genetics | 7 | 2.0 |
Blotting, Southern | 18 | 0.0 |
Expressed Sequence Tags | 10 | 2.0 |
Genetic Markers | 59 | 2.0 |
*Homozygote | 2 | 1.0 |
Loss of Heterozygosity/genetics | 3 | 2.0 |
Polymerase Chain Reaction | 53 | 0.0 |
Chromosomes, Artificial, Yeast | 35 | 8.0 |
*Chromosomes, Human, Pair 13 | 3 | 1.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
*Physical Chromosome Mapping | 6 | 3.0 |
Transcription Factors/genetics | 2 | 0.0 |
Bacteriophage P1/genetics | 5 | 20.0 |
Chromosomes, Human, Pair 1/*genetics | 2 | 0.0 |
Contig Mapping/*methods | 3 | 30.0 |
DNA, Neoplasm/genetics | 4 | 0.0 |
Physical Chromosome Mapping | 4 | 1.0 |
Aged, 80 and over | 11 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Prognosis | 10 | 0.0 |
Multivariate Analysis | 4 | 0.0 |
Survival Analysis | 8 | 0.0 |
Sensitivity and Specificity | 4 | 0.0 |
Time Factors | 5 | 0.0 |
Animals | 94 | 0.0 |
COS Cells | 2 | 0.0 |
DNA Primers/genetics | 13 | 0.0 |
DNA, Complementary/genetics | 8 | 0.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
Transfection | 7 | 0.0 |
Arylsulfatases/*genetics | 22 | 78.0 |
DNA/blood | 2 | 1.0 |
Hormones/blood | 2 | 1.0 |
*Translocation, Genetic | 9 | 1.0 |
X Chromosome | 11 | 2.0 |
Blotting, Northern | 6 | 0.0 |
Estradiol/metabolism | 2 | 2.0 |
Mice | 36 | 0.0 |
Mice, Nude | 3 | 0.0 |
Neoplasm Transplantation | 3 | 0.0 |
CHO Cells | 6 | 0.0 |
Drug Stability | 3 | 1.0 |
Hamsters | 21 | 0.0 |
Steryl-Sulfatase/*antagonists & inhibitors | 5 | 100.0 |
Structure-Activity Relationship | 11 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Amino Acid Sequence | 21 | 0.0 |
Cell Membrane/enzymology | 2 | 0.0 |
Y Chromosome/*genetics | 8 | 11.0 |
Chromosomes, Human, Pair 10/*genetics | 3 | 2.0 |
Cloning, Molecular | 34 | 0.0 |
Organ Specificity | 3 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Sequence Deletion | 5 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Infertility, Male/genetics | 2 | 10.0 |
Oligospermia/genetics | 4 | 22.0 |
Abnormalities, Multiple/*genetics | 4 | 1.0 |
Chromosomes, Human, Pair 17/*genetics | 2 | 1.0 |
*Gene Library | 6 | 11.0 |
Physical Chromosome Mapping/*methods | 2 | 10.0 |
Genetic Counseling | 3 | 1.0 |
Infertility, Male/*genetics | 5 | 11.0 |
Reproducibility of Results | 2 | 0.0 |
Alleles | 5 | 0.0 |
Bacterial Proteins/genetics | 2 | 2.0 |
*Bacterial Typing Techniques | 2 | 14.0 |
Variation (Genetics) | 2 | 0.0 |
DNA Primers | 36 | 0.0 |
Sarcoma/*genetics/pathology | 2 | 28.0 |
Haplotypes | 9 | 0.0 |
Polymorphism, Genetic | 11 | 0.0 |
Proteins/*genetics | 3 | 0.0 |
*Recombination, Genetic | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
DNA/genetics/isolation & purification | 3 | 1.0 |
DNA Probes | 7 | 0.0 |
Mental Retardation/*genetics | 2 | 0.0 |
Chromosomes, Artificial, Yeast/genetics | 8 | 7.0 |
Chromosomes, Bacterial/genetics | 4 | 17.0 |
Chromosomes, Human, Pair 2/genetics | 2 | 1.0 |
DNA/genetics | 10 | 0.0 |
Genotype | 10 | 0.0 |
Linkage (Genetics) | 31 | 1.0 |
Microsatellite Repeats | 9 | 0.0 |
Pedigree | 31 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Cohort Studies | 2 | 0.0 |
Extremities | 3 | 11.0 |
Life Tables | 3 | 1.0 |
*Nuclear Proteins | 2 | 0.0 |
Protein p53/*analysis | 2 | 1.0 |
Regression Analysis | 3 | 0.0 |
Retrospective Studies | 7 | 0.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Infant | 11 | 0.0 |
Dinucleotide Repeats | 2 | 2.0 |
*Linkage (Genetics) | 9 | 0.0 |
Species Specificity | 11 | 0.0 |
Chromosomes, Bacterial | 3 | 8.0 |
*Contig Mapping | 6 | 22.0 |
Lymphoproliferative Disorders/*genetics | 2 | 13.0 |
Mice, Inbred C57BL | 3 | 0.0 |
*Mutation | 3 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Dehydroepiandrosterone Sulfate/metabolism | 3 | 30.0 |
Genes, Recessive | 2 | 0.0 |
Questionnaires | 2 | 0.0 |
Databases, Factual | 3 | 1.0 |
Gene Library | 12 | 0.0 |
Genome | 3 | 1.0 |
Horses/*genetics | 3 | 14.0 |
*Trinucleotide Repeats | 2 | 1.0 |
*Chromosomes, Human, Pair 12 | 6 | 2.0 |
*Multigene Family | 3 | 0.0 |
Chromosomes, Human, Pair 12/*genetics | 2 | 1.0 |
Disease-Free Survival | 3 | 0.0 |
Drug Administration Schedule | 2 | 0.0 |
Infusions, Intravenous | 3 | 0.0 |
Italy | 2 | 0.0 |
Neoplasm Metastasis | 3 | 0.0 |
Sarcoma/*drug therapy | 3 | 33.0 |
Soft Tissue Neoplasms/*drug therapy | 2 | 100.0 |
Binding Sites | 4 | 0.0 |
Chromosomes, Human, Pair 1/genetics | 2 | 1.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Fetus/metabolism | 3 | 1.0 |
Gene Expression | 7 | 0.0 |
Genes, Structural/genetics | 2 | 0.0 |
Introns | 3 | 0.0 |
RNA-Binding Proteins/*genetics | 3 | 2.0 |
Sequence Homology, Nucleic Acid | 13 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Child, Preschool | 17 | 0.0 |
*Heterozygote | 3 | 0.0 |
X Chromosome/genetics | 3 | 1.0 |
Chromosomes, Human, Pair 6/*genetics | 2 | 1.0 |
Polymorphism, Restriction Fragment Length | 8 | 0.0 |
Arylsulfatases/metabolism | 3 | 33.0 |
Biological Markers/blood | 4 | 0.0 |
Liver/metabolism | 2 | 0.0 |
Hybrid Cells | 21 | 1.0 |
Pseudogenes | 3 | 1.0 |
*X Chromosome | 51 | 5.0 |
Skin Tests | 2 | 1.0 |
Amino Acid Substitution | 3 | 0.0 |
DNA, Complementary | 4 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
*Chromosomes, Human, Pair 1 | 4 | 0.0 |
DNA Fingerprinting/methods | 2 | 3.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 6 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Lymphocytes/enzymology | 2 | 2.0 |
Placenta/enzymology | 6 | 7.0 |
Cells, Cultured | 16 | 0.0 |
Chromosomes, Human, Pair 17/genetics | 2 | 1.0 |
*Glycoproteins | 2 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Multigene Family | 2 | 0.0 |
Rats | 15 | 0.0 |
Transcription Factors/*genetics | 3 | 0.0 |
*Sequence Tagged Sites | 21 | 52.0 |
Movement/*physiology | 2 | 5.0 |
Posture | 2 | 2.0 |
Chromosomes, Bacterial/*genetics | 2 | 40.0 |
Contig Mapping/methods | 2 | 16.0 |
*Genes, Structural | 8 | 0.0 |
Heterozygote | 7 | 0.0 |
17-Hydroxysteroid Dehydrogenases/*genetics | 2 | 33.0 |
Aromatase/*genetics | 2 | 8.0 |
Breast Neoplasms/*enzymology | 2 | 3.0 |
Interleukin-6/*genetics | 2 | 2.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Caspases/antagonists & inhibitors/metabolism | 2 | 2.0 |
Cytochrome c Group/antagonists & inhibitors/*metabolism/secretion | 2 | 100.0 |
HL-60 Cells/cytology/*drug effects/*enzymology | 2 | 66.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 2 | 1.0 |
Sodium Dodecyl Sulfate/pharmacology | 2 | 8.0 |
Sphingosine/*analogs & derivatives/antagonists & inhibitors/toxicity | 2 | 100.0 |
Chromosome Disorders | 3 | 0.0 |
*Chromosomes, Human, Pair 11 | 4 | 0.0 |
Cosmids | 13 | 3.0 |
Genetic Markers/genetics | 3 | 0.0 |
Amputation | 2 | 14.0 |
Combined Modality Therapy | 6 | 0.0 |
Cell Line | 23 | 0.0 |
In Vitro | 6 | 0.0 |
Ligands | 2 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Biotransformation | 3 | 0.0 |
Cytosol/enzymology | 6 | 3.0 |
Hydroxylation | 2 | 0.0 |
Kinetics | 17 | 0.0 |
Sulfotransferases/*metabolism | 5 | 19.0 |
Crosses, Genetic | 4 | 0.0 |
DNA Fingerprinting | 4 | 3.0 |
Chromosome Mapping/*methods | 17 | 9.0 |
*Chromosomes, Artificial, Yeast | 11 | 21.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
*Chromosomes, Human, Pair 17 | 5 | 0.0 |
Retinitis Pigmentosa/*genetics | 2 | 1.0 |
*Chromosomes, Human, Pair 21 | 6 | 3.0 |
Restriction Mapping | 18 | 0.0 |
English Abstract | 13 | 0.0 |
Ichthyosis, X-Linked/*genetics | 6 | 85.0 |
Leukocytes/*enzymology | 3 | 5.0 |
*Chromosomes, Bacterial | 2 | 40.0 |
DNA/analysis/genetics | 2 | 1.0 |
Lod Score | 2 | 0.0 |
Recombination, Genetic | 6 | 0.0 |
Cattle | 3 | 0.0 |
Microsomes/*enzymology | 2 | 4.0 |
Neoplasms/*etiology | 2 | 7.0 |
*Polymorphism, Genetic | 3 | 0.0 |
*Exons | 2 | 0.0 |
Chromosomes, Human, Pair 8/*genetics | 3 | 2.0 |
DNA, Neoplasm/analysis | 4 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Drug Screening Assays, Antitumor | 3 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
Japan | 4 | 0.0 |
Hyperthermia, Induced | 2 | 9.0 |
*Transcription Factors | 2 | 0.0 |
*Chromosomes, Human, Pair 22 | 4 | 1.0 |
Exercise Test | 2 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Amniocentesis | 3 | 3.0 |
DNA Mutational Analysis | 3 | 0.0 |
Estriol/*blood | 3 | 8.0 |
Ichthyosis/*diagnosis/*genetics | 2 | 66.0 |
Prenatal Diagnosis/*methods | 3 | 2.0 |
Arylsulfatases/*deficiency | 2 | 100.0 |
Prevalence | 3 | 0.0 |
Macropodidae/*genetics | 2 | 16.0 |
Follicle Stimulating Hormone/blood | 4 | 0.0 |
Luteinizing Hormone/blood | 4 | 0.0 |
Phenotype | 7 | 0.0 |
Testis/pathology | 2 | 4.0 |
Testosterone/blood | 4 | 0.0 |
Polymerase Chain Reaction/*methods | 6 | 1.0 |
Chromosomes/*genetics | 2 | 2.0 |
Chromosomes, Artificial, Bacterial/*genetics | 2 | 28.0 |
Chromosomes, Artificial, Yeast/*genetics | 7 | 28.0 |
Genomic Library | 5 | 1.0 |
DNA | 12 | 1.0 |
*Genetic Markers | 5 | 1.0 |
*Inversion, Chromosome | 2 | 2.0 |
*Repetitive Sequences, Nucleic Acid | 6 | 1.0 |
Chromosomes, Human, Pair 11/*genetics | 2 | 0.0 |
Alagille Syndrome/*genetics | 2 | 13.0 |
*Chromosomes, Human, Pair 20 | 2 | 1.0 |
Arylsulfatases/*deficiency/genetics | 5 | 100.0 |
Ichthyosis/enzymology | 2 | 100.0 |
Gene Frequency | 3 | 0.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Cell Line, Tumor | 5 | 0.0 |
Liver/enzymology | 4 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Cosmids/genetics | 2 | 3.0 |
Lymphatic Metastasis | 2 | 0.0 |
Centromere | 3 | 4.0 |
Likelihood Functions | 2 | 1.0 |
Brain Mapping | 2 | 1.0 |
Face | 2 | 8.0 |
Laterality/physiology | 2 | 3.0 |
Motion Perception/*physiology | 2 | 13.0 |
Aneuploidy | 2 | 1.0 |
Flow Cytometry | 2 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Dogs | 2 | 0.0 |
*Point Mutation | 3 | 0.0 |
*Blood Donors | 2 | 1.0 |
Enzyme Tests | 2 | 2.0 |
Exons | 4 | 0.0 |
Gene Amplification | 2 | 0.0 |
Arylsulfatases/*deficiency/*genetics | 2 | 100.0 |
Heterozygote Detection | 6 | 1.0 |
*Chromosomes, Human, Pair 7 | 3 | 1.0 |
*Genome, Human | 4 | 1.0 |
Arylsulfatases/*genetics/metabolism | 2 | 50.0 |
*Gene Transfer Techniques | 3 | 0.0 |
*Models, Genetic | 2 | 1.0 |
*Evolution | 2 | 1.0 |
Hominidae/*genetics | 4 | 2.0 |
Abnormalities, Multiple/genetics | 4 | 4.0 |
Sex Chromosome Aberrations/*genetics | 6 | 9.0 |
Cytosol/*enzymology | 4 | 7.0 |
*Chromosomes, Human, Pair 8 | 3 | 1.0 |
Werner Syndrome/*genetics | 2 | 6.0 |
Eye Proteins/*genetics | 2 | 1.0 |
Mutation | 3 | 0.0 |
*Chromosomes, Human, Pair 3 | 3 | 0.0 |
Chromosome Walking | 4 | 8.0 |
*Chromosomes, Human, Pair 18 | 2 | 1.0 |
Hybrid Cells/*radiation effects | 2 | 25.0 |
Cleft Lip/*genetics | 2 | 3.0 |
Cleft Palate/*genetics | 2 | 2.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Sampling Studies | 2 | 1.0 |
Neoplasm Recurrence, Local | 3 | 0.0 |
Models, Molecular | 2 | 0.0 |
Sex Factors | 3 | 0.0 |
*Sex Chromosome Aberrations | 4 | 13.0 |
Hela Cells | 2 | 0.0 |
Molecular Weight | 3 | 0.0 |
Nucleic Acid Hybridization | 6 | 0.0 |
Dosage Compensation (Genetics) | 4 | 2.0 |
Mice/*genetics | 3 | 1.0 |
Mice, Inbred Strains | 2 | 0.0 |
Mammals | 3 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Telomere | 2 | 3.0 |
Ichthyosis/genetics | 3 | 50.0 |
Reference Values | 4 | 0.0 |
*Chromosomes, Human, Pair 2 | 3 | 1.0 |
Cloning, Molecular/methods | 3 | 1.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
DNA/metabolism | 3 | 0.0 |
*Dosage Compensation (Genetics) | 8 | 4.0 |
*Chromosomes, Human, Pair 10 | 3 | 1.0 |
Clone Cells | 2 | 0.0 |
Escherichia coli | 2 | 0.0 |
*Genetic Vectors | 2 | 0.0 |
Plasmids | 3 | 0.0 |
Breast Neoplasms/*genetics | 3 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
Inversion, Chromosome | 2 | 3.0 |
Genes, Dominant | 2 | 0.0 |
Chromosomes, Human, Pair 21/*genetics | 2 | 2.0 |
Cricetulus | 2 | 0.0 |
Hybrid Cells/radiation effects | 2 | 4.0 |
Fibroblasts | 2 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Hydroxylamines/*metabolism | 2 | 66.0 |
Liver/*enzymology | 2 | 0.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Muridae/genetics | 2 | 3.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Risk Factors | 5 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Swine/*genetics | 2 | 1.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Sex Chromosome Aberrations | 3 | 13.0 |
Skin/pathology | 2 | 0.0 |
Dehydroepiandrosterone Sulfate | 2 | 2.0 |
Estrone/*analogs & derivatives/metabolism/pharmacology | 2 | 66.0 |
Blotting, Western | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Rabbits | 3 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Chromosomes, Human, Pair 1 | 2 | 0.0 |
Biopsy | 3 | 0.0 |
Genes, Structural | 4 | 0.0 |
Human Genome Project | 2 | 12.0 |
*Chromosomes, Fungal | 2 | 8.0 |
*Prenatal Diagnosis | 2 | 0.0 |
Chromosomes, Fungal | 4 | 6.0 |
DNA, Single-Stranded | 2 | 2.0 |
Estrone/analogs & derivatives/metabolism | 2 | 100.0 |
Leukocytes/enzymology | 5 | 4.0 |
Binding, Competitive | 3 | 0.0 |
Steryl-Sulfatase/*antagonists & inhibitors/metabolism | 3 | 100.0 |
Sulfatases/*genetics | 12 | 63.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Breast Neoplasms/drug therapy/enzymology | 2 | 28.0 |
Enzyme Inhibitors/*chemical synthesis/*pharmacology | 2 | 14.0 |
Estrogen Receptor alpha | 2 | 0.0 |
Arylsulfatases/deficiency | 2 | 100.0 |
Steryl-Sulfatase/*deficiency/genetics | 2 | 100.0 |
Amniotic Fluid/cytology/*enzymology | 2 | 100.0 |
*In Situ Hybridization, Fluorescence | 2 | 1.0 |
Aromatase/metabolism | 2 | 14.0 |
Aromatase Inhibitors | 2 | 10.0 |
Estrogens/*biosynthesis | 3 | 33.0 |
*Chromosomes, Human, X | 2 | 6.0 |
Cell Division/drug effects | 3 | 0.0 |
Estrogens/metabolism | 2 | 2.0 |
Ichthyosis/enzymology/*genetics | 4 | 100.0 |
Swine | 3 | 0.0 |
X Chromosome/*ultrastructure | 3 | 12.0 |
Ichthyosis/*genetics | 2 | 40.0 |
*Cloning, Molecular | 2 | 0.0 |
Fibroblasts/enzymology | 6 | 3.0 |
Sulfatases/*analysis | 2 | 100.0 |
*Genes, Recessive | 2 | 1.0 |
Skin/enzymology | 3 | 9.0 |
Sulfatases/*deficiency | 4 | 50.0 |
India | 2 | 0.0 |
Arylsulfatases/genetics/*metabolism | 2 | 100.0 |
Ichthyosis/complications/enzymology/*genetics | 2 | 100.0 |
Sulfatases/*deficiency/genetics | 4 | 100.0 |
DNA Restriction Enzymes | 3 | 0.0 |
Sulfatases/deficiency/*genetics | 2 | 66.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Sulfatases/analysis/*genetics | 2 | 100.0 |
Blood Group Antigens/genetics | 3 | 5.0 |
Cisplatin/administration & dosage/*metabolism | 2 | 100.0 |
Infusions, Parenteral | 2 | 1.0 |
Sex Chromosomes/*physiology | 3 | 60.0 |
Molecular Structure | 3 | 0.0 |
*Alleles | 3 | 0.0 |
*Sex Chromosomes | 5 | 16.0 |
Hybrid Cells/physiology | 2 | 7.0 |
Radiotherapy Dosage | 2 | 1.0 |
Estrone/*analogs & derivatives/pharmacology | 2 | 50.0 |
Microsomes/drug effects/enzymology | 2 | 10.0 |
